Diadema Partners »

Evolus shares owned by Diadema Partners

Quarter-by-quarter ownership of Evolus (EOLS) shares owned by Diadema Partners from 13F filings

Historical chart of Diadema Partners investment in Evolus

Tip: Access up to 7 years of quarterly data

All positions including Evolus held by Diadema Partners consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Evolus by Diadema Partners

Quarter filed Position value Share count Share price at filing
2026-06-30 $1.4M 200k 6.94
2026-03-31 $515k 125k 4.11
2025-12-31 $790k 119k 6.65

More positions owned by Diadema Partners

Abivax Sa Sponsored Ads Call Option (ABVX)
Viking Therapeutics (VKTX)
Bristol Myers Squibb Put Option (BMY)
Amgen Call Option (AMGN)
United Therapeutics Corporation (UTHR)
Revolution Medicines (RVMD)
Uniqure Nv SHS Put Option (QURE)
Novartis Sponsored Adr Call Option (NVS)
Kodiak Sciences Call Option (KOD)
Capricor Therapeutics Com New Put Option (CAPR)
Cogent Biosciences (COGT)
Bridgebio Pharma Note 1.750% 3/0 (Principal)
Corcept Therapeutics Incorporated Call Option (CORT)
BioMarin Pharmaceutical (BMRN)
Kymera Therapeutics Call Option (KYMR)

View all positions for Diadema Partners

Top funds holding Evolus

Nantahala Capital Management
BlackRock
Braidwell
Frazier Life Sciences Management
Perceptive Advisors
Vanguard Capital Management
Stonepine Capital Management
Millennium Management
Geode Capital Management
Point72 Asset Management
Gail Mannix
Armistice Capital
State Street Corporation
Rice Hall James & Associates
Goldman Sachs Group

View all funds holding Evolus